Fruquintinib PopPK in Refractory Metastatic CRC
Indication: Previously treated metastatic colorectal cancer
Population PK simulator for fruquintinib, an oral VEGFR1/2/3 inhibitor used in previously treated metastatic colorectal cancer. Supports exposure assessment for antiangiogenic oncology dosing.
Drug Overview
Clinical Context
- Molecular Target
- VEGFR1, VEGFR2, and VEGFR3
- Drug Class
- VEGFR Tyrosine Kinase Inhibitor
- Therapeutic Area
- Oncology / Metastatic Colorectal Cancer
- Indication
- Previously treated metastatic colorectal cancer
- Route of Administration
- Oral
Model Information
- Model Type
- Population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Fruquintinib allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK model characterizes the pharmacokinetics of this vegfr tyrosine kinase inhibitor following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Fruquintinib PK simulator?
This is a free, interactive pharmacokinetic simulator for Fruquintinib used in Previously treated metastatic colorectal cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Fruquintinib belong to?
Fruquintinib is classified as a VEGFR Tyrosine Kinase Inhibitor that targets VEGFR1, VEGFR2, and VEGFR3. It is used in the Oncology / Metastatic Colorectal Cancer therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Fruquintinib. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Ready to Simulate?
Launch the Fruquintinib simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community